Private Capital Advisors Inc. Has $511,000 Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR

Posted by Stanley Muller on May 24th, 2026

Private Capital Advisors Inc. trimmed its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) by 86.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,348 shares of the company’s stock after selling 47,837 shares during the period. Private Capital Advisors Inc.’s holdings in Structure Therapeutics were worth $511,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. CWM LLC lifted its position in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Structure Therapeutics by 530.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after buying an additional 901 shares during the last quarter. State of Wyoming bought a new stake in shares of Structure Therapeutics during the second quarter worth approximately $28,000. Banque Cantonale Vaudoise bought a new stake in shares of Structure Therapeutics during the fourth quarter worth approximately $205,000. Finally, ProShare Advisors LLC bought a new stake in shares of Structure Therapeutics during the fourth quarter worth approximately $206,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $39.19 on Friday. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $15.80 and a 52 week high of $94.90. The company has a market capitalization of $2.78 billion, a PE ratio of -45.05 and a beta of -1.31. The company has a 50 day moving average price of $46.77 and a two-hundred day moving average price of $56.65.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. On average, sell-side analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.29 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on GPCR shares. Wolfe Research started coverage on shares of Structure Therapeutics in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Wall Street Zen downgraded shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Canaccord Genuity Group started coverage on shares of Structure Therapeutics in a research note on Monday, April 27th. They set a “buy” rating and a $101.00 price target for the company. William Blair reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Finally, Citizens Jmp dropped their price target on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research note on Friday, February 27th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.25.

View Our Latest Analysis on Structure Therapeutics

Structure Therapeutics Profile

(Free Report)

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.